Displaying One Session

Myriad Genetics - Developments in precision medicine for breast and ovarian cancers  (ID 136)

Time
08:45 - 10:15

Introduction by Chairperson (ID 4795)

The importance of biomarker-led decisions for PARP inhibitor maintenance in ovarian cancer (ID 4796)

Implementing Myriad’s HRD testing in a European molecular pathology laboratory (ID 4797)

LIVE myChoice Q&A (ID 4798)

The value of gene expression testing in breast cancer: can premenopausal patients safely forego chemotherapy (ID 4799)

LIVE EndoPredict Q&A (ID 4800)